AdAlta Locks Down Final Patent for AD-214, Completing Global IP Shield to 2036
AdAlta (ASX: 1AD) has secured a composition of matter patent for its anti-fibrotic therapeutic AD-214 from the Canadian Intellectual Property Office, completing global intellectual property protection across all major commercial markets. Canadian Patent Number 2,973,317 has an expiry date of January 2036.
AdAlta secures Canadian patent for AD-214, completing global IP protection
The Canadian patent grant represents the final piece in a comprehensive intellectual property strategy covering AD-214 across key commercial markets and manufacturing jurisdictions. The therapeutic candidate is now protected in the US, Canada, European Union, and Japan, alongside manufacturing locations in India and China.
Composition of matter patents represent the strongest form of intellectual property protection available to pharmaceutical developers. These patents protect the actual molecular structure of a therapeutic, rather than just its method of use or manufacturing process, making them critical assets during licensing negotiations and partner due diligence processes.
When big ASX news breaks, our subscribers know first
What are composition of matter patents and why do they matter?
A composition of matter patent protects the fundamental chemical or molecular structure of a drug candidate, not merely how it is made or used. This distinction provides broader protection than other patent types, preventing competitors from developing therapeutically similar molecules even if they use different manufacturing methods.
For pharmaceutical companies seeking licensing partners, composition of matter patents are often a non-negotiable requirement. Potential partners prioritise this form of IP protection because it offers the most robust defence against generic competition and provides clearer commercial exclusivity during the patent term.
Geographic coverage and supply chain protection
The AdAlta AD-214 Canadian patent completes protection across:
- Commercial markets: United States, Canada, European Union, Japan
- Manufacturing locations: India, China
- Protection duration: Until 2036
This geographic coverage strategy protects both demand-side markets where the therapy would be sold and supply-side locations where pharmaceutical manufacturing typically occurs, creating a comprehensive barrier to competition.
The next major ASX story will hit our subscribers first
Additional patent applications could extend protection to 2043
AdAlta has filed additional patent applications covering dosing regimens and methods of treatment for AD-214. If granted, these applications would extend intellectual property protection until 2043, providing an additional seven years of commercial exclusivity beyond the current composition of matter patents.
Tim Oldham, CEO and Managing Director
“Composition of matter patents are the strongest form of patent protection and a key part of the data package partners expect from us. This Canadian patent completes the protection of AD-214 in all major commercial markets and its potential supply chain.”
AD-214 partnering status
AD-214 has completed two successful Phase I clinical studies and is currently available for partnering discussions with pharmaceutical companies. The therapeutic candidate targets Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis as its primary indications.
The completion of comprehensive global patent protection removes a potential barrier during partnering negotiations, positioning AD-214 as a partner-ready asset with robust intellectual property coverage across all commercially relevant jurisdictions.
Get the Next Biotech Breakthrough Before the Market Reacts
Join 20,000+ investors receiving FREE breaking ASX biotech news and analysis delivered to your inbox within minutes of release. Click the “Free Alerts” button at StockWire X to get real-time alerts the moment market-moving announcements drop.